PL3319612T3 - Oksysterole i sposoby ich stosowania - Google Patents

Oksysterole i sposoby ich stosowania

Info

Publication number: PL3319612T3
Authority: PL; Poland
Prior art keywords: oxysterols; application
Prior art date: 2015-07-06

Application number

PL16821926T

Other languages

English (en)

Inventor

Francesco G. Salituro

Albert Jean Robichaud

Gabriel Martinez Botella

Boyd L. Harrison

Original Assignee

Sage Therapeutics, Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-07-06

Filing date

2016-07-06

Publication date

2021-12-20

2016-07-06 Application filed by Sage Therapeutics, Inc. filed Critical Sage Therapeutics, Inc.

2021-12-20 Publication of PL3319612T3 publication Critical patent/PL3319612T3/pl

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
- C07J41/0061—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives one of the carbon atoms being part of an amide group
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
- C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
- C07J7/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa
- C07J7/002—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa not substituted in position 16
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
- C07J13/005—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17 with double bond in position 16 (17)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
- C07J13/007—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17 with double bond in position 17 (20)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
- C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
- C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Diabetes (AREA)
Anesthesiology (AREA)
Hematology (AREA)
Obesity (AREA)
Psychiatry (AREA)
Psychology (AREA)
Pain & Pain Management (AREA)
Epidemiology (AREA)
Hospice & Palliative Care (AREA)
Heart & Thoracic Surgery (AREA)
Vascular Medicine (AREA)
Cardiology (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Ophthalmology & Optometry (AREA)
Rheumatology (AREA)
Urology & Nephrology (AREA)
Steroid Compounds (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

PL16821926T 2015-07-06 2016-07-06 Oksysterole i sposoby ich stosowania PL3319612T3 (pl)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US201562189068P	2015-07-06	2015-07-06
US201662332931P	2016-05-06	2016-05-06
PCT/US2016/041175 WO2017007840A1 (en)	2015-07-06	2016-07-06	Oxysterols and methods of use thereof
EP16821926.9A EP3319612B1 (en)	2015-07-06	2016-07-06	Oxysterols and methods of use thereof

Publications (1)

Publication Number	Publication Date
PL3319612T3 true PL3319612T3 (pl)	2021-12-20

Family

ID=57686127

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
PL16821926T PL3319612T3 (pl)	2015-07-06	2016-07-06	Oksysterole i sposoby ich stosowania
PL20214736.9T PL3812392T3 (pl)	2015-07-06	2016-07-06	Oksysterole i sposoby ich stosowania

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
PL20214736.9T PL3812392T3 (pl)	2015-07-06	2016-07-06	Oksysterole i sposoby ich stosowania

Country Status (30)

Country	Link
US (3)	US11117924B2 (pl)
EP (3)	EP3319612B1 (pl)
JP (4)	JP2018519328A (pl)
KR (2)	KR20180026742A (pl)
CN (3)	CN118994288A (pl)
AU (3)	AU2016289971C1 (pl)
CA (1)	CA2991313C (pl)
CO (1)	CO2018000589A2 (pl)
CY (1)	CY1124620T1 (pl)
DK (2)	DK3319612T3 (pl)
ES (2)	ES3036110T3 (pl)
FI (1)	FI3812392T3 (pl)
HR (2)	HRP20211282T1 (pl)
HU (2)	HUE071964T2 (pl)
IL (3)	IL282048B2 (pl)
LT (2)	LT3812392T (pl)
MA (1)	MA54851A (pl)
MD (1)	MD3319612T2 (pl)
MX (3)	MX390271B (pl)
MY (1)	MY197698A (pl)
PE (1)	PE20180482A1 (pl)
PH (2)	PH12020551586A1 (pl)
PL (2)	PL3319612T3 (pl)
PT (2)	PT3812392T (pl)
RS (2)	RS62220B1 (pl)
RU (1)	RU2742333C2 (pl)
SG (1)	SG10202002655VA (pl)
SI (2)	SI3812392T1 (pl)
SM (2)	SMT202100476T1 (pl)
WO (1)	WO2017007840A1 (pl)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20150158903A1 (en)	2011-09-08	2015-06-11	Sage Therapeutics, Inc.	Neuroactive steroids, compositions, and uses thereof
LT2968369T (lt)	2013-03-13	2018-12-27	Sage Therapeutics, Inc.	Neuroaktyvūs steroidai ir jų panaudojimo būdai
ES2970222T3 (es)	2014-06-18	2024-05-27	Sage Therapeutics Inc	Oxiesteroles y procedimientos de uso de los mismos
RS62220B1 (sr)	2015-07-06	2021-09-30	Sage Therapeutics Inc	Oksisteroli i postupci njihovog korišćenja
MX376833B (es)	2015-07-06	2025-03-07	Sage Therapeutics Inc	Oxiesteroles y metodos de uso de los mismos.
MA42409A (fr) *	2015-07-06	2018-05-16	Sage Therapeutics Inc	Oxystérols et leurs procédés d'utilisation
CN114272249A (zh)	2016-04-01	2022-04-05	萨奇治疗股份有限公司	氧甾醇及其使用方法
US10752653B2 (en)	2016-05-06	2020-08-25	Sage Therapeutics, Inc.	Oxysterols and methods of use thereof
AU2017292870B2 (en)	2016-07-07	2021-10-07	Sage Therapeutics, Inc.	Oxysterols and methods of use thereof
EP3519422B1 (en)	2016-09-30	2022-08-31	Sage Therapeutics, Inc.	C7 substituted oxysterols and these compounds for use as nmda modulators
ES2952106T3 (es)	2016-10-18	2023-10-27	Sage Therapeutics Inc	Oxisteroles y procedimientos de utilización de los mismos
KR20250054838A (ko)	2016-10-18	2025-04-23	세이지 테라퓨틱스, 인크.	옥시스테롤 및 그의 사용 방법
US10857163B1 (en)	2019-09-30	2020-12-08	Athenen Therapeutics, Inc.	Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof
CN113121631B (zh) *	2021-03-25	2023-02-03	西北农林科技大学	一种羊毛甾烷灵芝三萜类化合物、制备方法及应用
WO2022261510A1 (en)	2021-06-11	2022-12-15	Sage Therapeutics, Inc.	Neuroactive steroid for the treatment of alzheimer's disease
US20250064833A1 (en)	2021-12-13	2025-02-27	Sage Therapeutics, Inc.	Combination of muscarinic receptor positive modulators and nmda positive allosteric modulators
WO2025020191A1 (zh) *	2023-07-27	2025-01-30	珂阑(上海)医药科技有限公司	甾类化合物、其制备方法和应用

Family Cites Families (125)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2259698A (en)	1938-05-07	1941-10-21	Rare Chemicals Inc	Physiologically effective substance and process of preparing same
US2594323A (en)	1948-07-22	1952-04-29	Upjohn Co	24-substituted delta 5-cholene-3, 24-diols
US2673206A (en)	1950-06-07	1954-03-23	Schering Corp	25-ethinyl steroids
US3079385A (en)	1961-01-24	1963-02-26	Roussel Uclaf	Novel process of preparation of polyhydroxylated pregnanes
US3206459A (en)	1962-10-19	1965-09-14	Syntex Corp	10alpha-pregnan-19-ol derivatives
JPS5324071B2 (pl)	1974-04-30	1978-07-18
US4071625A (en)	1974-05-13	1978-01-31	Richardson-Merrell Inc.	19-Oxygenated-5α-androstanes for the enhancement of libido
CH628907A5 (en)	1975-10-10	1982-03-31	Hoffmann La Roche	Process for the preparation of 24,25-dihydroxycholesterol derivatives
JPS5840960B2 (ja)	1976-12-28	1983-09-08	帝人株式会社	ヒドロキシコレステロ−ル立体異性体間の相互変換法
US4183852A (en)	1977-07-18	1980-01-15	Kaiser Emil T	Process for preparing 25-hydroxycholesterol
JPS54163565A (en)	1978-06-09	1979-12-26	Teijin Ltd	24255epoxyy3beta 266 dihydroxyychlestoo55ene or protected derivative of hydroxyl group thereof and production
US4174345A (en)	1978-08-01	1979-11-13	Kaiser Emil T	Synthesis of steroids
US4269777A (en)	1979-05-21	1981-05-26	Wisconsin Alumni Research Foundation	Isotopically labeled vitamin D derivatives and processes for preparing same
JPS5735597A (en)	1980-08-13	1982-02-26	Teijin Ltd	25,26-epoxy-3beta,24-dihydroxycholest-5-ene or its hydroxyl- protected derivative and their preparation
JPS61254599A (ja)	1985-05-07	1986-11-12	Sumitomo Pharmaceut Co Ltd	コレステロ−ルのフツ素誘導体
ATE45347T1 (de)	1985-05-30	1989-08-15	Taisho Pharmaceutical Co Ltd	Vitamin d3-derivate.
JPS62187485A (ja)	1986-02-13	1987-08-15	Teijin Ltd	２４，２５−エポキシコレステロ−ル類の製造法
US5232917A (en)	1987-08-25	1993-08-03	University Of Southern California	Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series
US5376645A (en)	1990-01-23	1994-12-27	University Of Kansas	Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
AU698834B2 (en)	1993-05-24	1998-11-12	Purdue Pharma Ltd.	Methods and compositions for inducing sleep
IL110309A0 (en)	1993-07-15	1994-10-21	Univ Kentucky Res Found	A method of protecting against neuron loss
NZ282939A (en)	1994-02-14	1998-08-26	Cocensys Inc	Androstanes and pregnanes for allosteric modulation of gaba receptors
TW385308B (en)	1994-03-04	2000-03-21	Merck & Co Inc	Prodrugs of morpholine tachykinin receptor antagonists
US5595996A (en)	1994-10-25	1997-01-21	Merck & Co., Inc.	7-substituted 4-aza cholanic acid derivatives and their use
WO1996016076A1 (en)	1994-11-23	1996-05-30	Cocensys, Inc.	Androstane and pregnane series for allosteric modulation of gaba receptor
JPH08268917A (ja)	1995-03-31	1996-10-15	D D S Kenkyusho:Kk	癌組織への移行性の高い制癌剤
KR19990022323A (ko)	1995-06-06	1999-03-25	씨. 랜 낸시	안드로스탄 및 프레그난 시리즈의 신경활성 스테로이드
US6780853B1 (en) *	1995-06-06	2004-08-24	Euro-Celtique S.A.	Neuroactive steroids of the androstane and pregnane series
US5792635A (en)	1995-06-07	1998-08-11	Magainin Pharmaceuticals, Inc.	Method of inhibiting the sodium/proton exchanger NHE3 and method of inhibiting growth by administering squalamine
US6645953B2 (en)	1995-06-23	2003-11-11	Novo Nordisk A/S	Meiosis regulating compounds
RU2182909C2 (ru)	1995-06-23	2002-05-27	Ново Нордиск А/С	Стероиды, способ регулирования мейоза
US5888996A (en)	1995-07-26	1999-03-30	Trustees Of Boston University	Inhibition of NMDA receptor activity and modulation of glutamate-mediated synaptic activity
EP0840612A1 (en)	1995-07-24	1998-05-13	Trustees Of Boston University	Inhibition of nmda receptor activity by pregnenolone sulfate derivatives
WO1997042215A1 (en)	1996-05-06	1997-11-13	Bionumerik Pharmaceuticals, Inc.	Process for preparing 27-hydroxy cholesterol and related derivatives
JPH09328498A (ja)	1996-06-10	1997-12-22	Teijin Ltd	２４，２５−ジヒドロキシコレステロールの製造法およびその合成中間体
AU3967297A (en)	1996-08-01	1998-02-25	Cocensys, Inc.	Use of gaba and nmda receptor ligands for the treatment of migraine headache
US6122371A (en)	1997-07-22	2000-09-19	Atwell; Ronald C.	Apparatus for protecting coin-operated telephones from vandalism and larceny
WO1999058497A1 (en)	1998-05-11	1999-11-18	Novo Nordisk A/S	Substituted guanidines and diaminonitroethenes, their preparation and use
IL139241A0 (en)	1998-05-13	2001-11-25	Novo Nordisk As	Meiosis regulating compounds
US8541600B2 (en) *	1998-11-24	2013-09-24	Harbor Therapeutics, Inc.	11-aza, 11-thia and 11-oxa sterol compounds and compositions
US6376530B1 (en) *	1999-05-10	2002-04-23	Merck & Co., Inc.	Cyclic amidines useful as NMDA NR2B antagonists
GB9910934D0 (en)	1999-05-11	1999-07-14	Res Inst Medicine Chem	Chemical compounds
CN1111167C (zh)	1999-10-22	2003-06-11	中国科学院上海有机化学研究所	3β－羟基－5－胆烯酸酯类衍生物、合成方法及其用途
CN1098273C (zh)	1999-11-12	2003-01-08	中国科学院上海有机化学研究所	高立体选择性的合成24r,25－和24s,25－二羟基甾体化合物
GB0000228D0 (en)	2000-01-06	2000-03-01	Phytopharm Plc	Fluoro substituted sapogenins and their use
GB0019290D0 (en)	2000-08-04	2000-09-27	Symphar Sa	Methods for inducing apolipoprotein E secretion
GR1003861B (el)	2000-12-29	2002-04-11		Νεα νευροστεροειδη που αλληλεπιδρουν με τον υποδοχεα gabaa.
GB0107822D0 (en)	2001-03-28	2001-05-23	Phytopharm Plc	Sapogenin derivatives their synthesis and use methods based upon their use
DK1392713T3 (da)	2001-05-03	2008-02-18	Univ Chicago	Lever-X-receptoragonister
US20070197484A1 (en)	2001-05-03	2007-08-23	Ching Song	Method of treating disorder related to high cholesterol concentration
EP1450816A4 (en)	2001-11-08	2008-02-13	Univ Chicago	METHOD OF TREATING DISORDERS RELATED TO HIGH CHOLESTEROL RATE
AU2002360489A1 (en)	2001-12-07	2003-06-23	The Regents Of The University Of California	Treatment for age-related macular degeneration
CN102727501A (zh)	2002-03-27	2012-10-17	菲特法姆股份有限公司	皂角苷配基及其衍生物的用途
NZ547344A (en)	2002-03-27	2007-11-30	Phytopharm Plc	Therapeutic methods and uses of sapogenins and their derivatives
GB0216621D0 (en) *	2002-07-17	2002-08-28	Imaging Res Solutions Ltd	Imaging compounds
US6933312B2 (en)	2002-10-07	2005-08-23	Agouron Pharmaceuticals, Inc.	Pyrazole derivatives
CA2506568A1 (en) *	2002-11-22	2004-06-10	Merck & Co., Inc.	2-[(4-benzyl)-1-piperidinyl)methyl]benzimidazole-5-ol derivatives as nr2b receptor antagonists
WO2004055201A2 (en)	2002-12-13	2004-07-01	Bayer Healthcare Ag	Cholesterol 24-hydroxylase (cyp46) as therapeutic target for the treatment of alzheimer's disease
FR2850023B1 (fr)	2003-01-17	2007-04-06	Mapreg	Medicaments pour le systeme nerveux
GB0403889D0 (en)	2004-02-21	2004-03-24	Univ Edinburgh	Uses of er-beta modulators
WO2006037016A2 (en)	2004-09-27	2006-04-06	The Regents Of The University Of California	Novel therapy for treatment of chronic degenerative brain diseases and nervous system injury
US20070032464A1 (en)	2004-10-08	2007-02-08	Shutsung Liao	Methods of treating cancers
AU2005302452B2 (en)	2004-11-01	2010-12-09	Seo Hong Yoo	Methods and compositions for reducing neurodegeneration in Amyotrophic Lateral Sclerosis
CA2643732C (en)	2006-02-27	2012-08-21	The Regents Of The University Of California	Oxysterol compounds and the hedgehog pathway
CN101164540A (zh)	2006-08-03	2008-04-23	中山大学	海洋甾体化合物在制备治疗神经元损伤药物中的应用
GB0619860D0 (en)	2006-10-06	2006-11-15	Birkeland Innovasjon As	Treatment of insulin resistance and disorders associated therewith
WO2008057468A1 (en)	2006-11-02	2008-05-15	Curis, Inc.	Small organic molecule regulators of cell proliferation
ES2607852T3 (es)	2006-11-21	2017-04-04	Umecrine Ab	El uso de esteroides de pregnano y androstano para la fabricación de una composición farmacéutica para el tratamiento de trastornos del SNC
EP2170828B1 (en)	2007-06-20	2012-11-21	Auspex Pharmaceuticals, Inc.	Substituted n-aryl pyridinones as fibrotic inhibitors
GB0712494D0 (en)	2007-06-27	2007-08-08	Isis Innovation	Substrate reduction therapy
CA2703497A1 (en)	2007-11-06	2009-05-14	N.V. Organon	A method of hormone suppression in humans
CA2707663C (en)	2007-12-03	2017-05-30	The Regents Of The University Of California	Oxysterols for activation of hedgehog signaling, osteoinduction, antiadipogenesis, and wnt signaling
WO2009090063A1 (en)	2008-01-16	2009-07-23	Jado Technologies Gmbh	Steroid sapogenin, androstane and triterpenoid sapogenin derivatives for the treatment and prevention of infectious diseases
US8273737B2 (en)	2008-01-25	2012-09-25	Merck Sharp & Dohme Corp.	Quinolizidinone M1 receptor positive allosteric modulators
CN101951930A (zh) *	2008-02-19	2011-01-19	阿奈斯特药品株式会社	对身体功能的恢复有用的口服或经肠组合物
US8497122B2 (en) *	2008-04-11	2013-07-30	Washington University	Biomarkers for Niemann-pick C disease and related disorders
JP2011520815A (ja)	2008-05-09	2011-07-21	エモリー・ユニバーシテイ	精神神経障害治療のためのｎｍｄａ受容体拮抗薬
JP5780521B2 (ja) *	2008-05-28	2015-09-16	リベラジェン・バイオファーマ・インコーポレイテッドＲｅｖｅｒａＧｅｎＢｉｏＰｈａｒｍａ，Ｉｎｃ．	疾患を治療するための、ＮＦ−κＢの非ホルモン性ステロイド調節因子
WO2010065709A2 (en)	2008-12-03	2010-06-10	Amin Khan	Hydroxamic acid derivatives, preparation and therapeutic uses thereof
US20120040916A1 (en)	2008-12-22	2012-02-16	Massachusetts Institute Of Technology	Molecular inhibitors of the wnt/beta-catenin pathway
US8822462B2 (en)	2009-01-28	2014-09-02	Emory University	Subunit selective NMDA receptor potentiators for the treatment of neurological conditions
EP2459581A4 (en)	2009-07-29	2012-12-26	Univ Chicago	LIVER X-RECEPTOR AGONISTS
WO2011028794A2 (en)	2009-09-01	2011-03-10	Lazarus Therapeutics, Inc.	Treatment of huntington's disease with cycloserine and an nmda receptor antagonist
FR2953138B1 (fr)	2009-12-02	2015-10-16	Assist Publ Hopitaux Marseille	Composes aminosteroidiens pour une application topique locale pour la decolonisation cutaneo-muqueuse de staphylococcus aureus
JP2011135864A (ja) *	2009-12-30	2011-07-14	Korea Univ Research & Business Foundation	Ｏｃｔ４及びＢｍｉ１、またはその上位調節子を用いて体細胞から胚幹細胞類似細胞への逆分化を誘導する組成物及びこれを用いた胚幹細胞類似細胞の製造方法
KR101692275B1 (ko)	2010-02-11	2017-01-04	노오쓰웨스턴 유니버시티	２차 구조 안정화된 ｎｍｄａ 수용체 조절제 및 그의 용도
US8247436B2 (en)	2010-03-19	2012-08-21	Novartis Ag	Pyridine and pyrazine derivative for the treatment of CF
GB201008047D0 (en) *	2010-05-14	2010-06-30	Ge Healthcare Ltd	Method of synthesis
US20120035156A1 (en)	2010-08-09	2012-02-09	Daniela Alberati	Combination of glyt1 compound with antipsychotics
US8969525B2 (en)	2010-11-09	2015-03-03	Enzo Life Sciences, Inc.	Hydroxycholesterol immunoassay
US20150031655A1 (en)	2011-04-15	2015-01-29	University Of North Dakota	Combination of liver x receptor modulator and estrogen receptor modulator for the treatment of age-related diseases
EP2714081A4 (en)	2011-05-27	2015-09-09	Cytocure Llc	METHODS, COMPOSITIONS AND KIT FOR CREAM TREATMENT
JP2014521662A (ja)	2011-07-29	2014-08-28	ザリージェンツオブザユニバーシティオブカリフォルニア	ＧＡＢＡＡ受容体のモジュレーターとしての新規な１７β−ヘテロアリール置換ステロイド
US20150158903A1 (en) *	2011-09-08	2015-06-11	Sage Therapeutics, Inc.	Neuroactive steroids, compositions, and uses thereof
HUE043171T2 (hu)	2011-10-07	2019-08-28	Takeda Pharmaceuticals Co	Neurodegeneratív betegségek kezelésére hasznos 1-arilkarbonil-4-oxi-piperidinvegyületek
ES2738526T3 (es)	2011-10-14	2020-01-23	Sage Therapeutics Inc	Compuestos 19-norpregnano 3,3-disustituidos, composiciones y usos de los mismos
WO2013163455A2 (en)	2012-04-25	2013-10-31	The Regents Of The University Of California	A drug screening platform for rett syndrome
US9737522B2 (en)	2012-08-09	2017-08-22	Emory University	NMDA receptor modulators and uses related thereto
US20140149272A1 (en)	2012-08-17	2014-05-29	Trueex Group Llc	Interoffice bank offered rate financial product and implementation
AU2013305563B2 (en) *	2012-08-24	2018-09-27	Integurx Therapeutics, Llc	Chemical compositions and methods for enhancing transdermal delivery of therapeutic agents
BR112015014397B1 (pt)	2012-12-18	2021-02-02	Washington University	composto, composição farmacêutica e uso de um composto
EP2948152A4 (en)	2013-01-23	2016-12-14	Sphaera Pharma Private Ltd	NOVEL COMPOUNDS OF 11-BETA HYDROXY-STEROIDS FOR USE IN MITOCHONDRIA BIOGENESIS AND DISEASES RELATED TO MITOCHONDRIA DYSFUNCTION OR ADDITIONAL
MX2015009773A (es)	2013-01-29	2016-08-05	Aptinyx Inc	Moduladores de receptores nmda de espiro-lactama y sus usos.
IL286970B2 (en) *	2013-03-13	2024-11-01	Sage Therapeutics Inc	Neuroactive steroids and methods of use thereof
LT2968369T (lt)	2013-03-13	2018-12-27	Sage Therapeutics, Inc.	Neuroaktyvūs steroidai ir jų panaudojimo būdai
EP3049089B1 (en)	2013-09-25	2019-08-21	Van Andel Research Institute	Highly potent glucocorticoids
CN103655582B (zh) *	2013-11-30	2015-05-27	浙江大学	一种环氧甾醇组合物及制备和用途
ES2970222T3 (es)	2014-06-18	2024-05-27	Sage Therapeutics Inc	Oxiesteroles y procedimientos de uso de los mismos
US10238664B2 (en)	2014-07-09	2019-03-26	Duke University	Compositions and methods for the repair of myelin
US10016095B2 (en) *	2014-10-03	2018-07-10	Progressive International Corporation	Salad spinner
EP3204011A4 (en)	2014-10-07	2018-06-20	Sage Therapeutics, Inc.	Neuroactive compounds and methods of use thereof
MX376833B (es)	2015-07-06	2025-03-07	Sage Therapeutics Inc	Oxiesteroles y metodos de uso de los mismos.
MA42409A (fr)	2015-07-06	2018-05-16	Sage Therapeutics Inc	Oxystérols et leurs procédés d'utilisation
RS62220B1 (sr) *	2015-07-06	2021-09-30	Sage Therapeutics Inc	Oksisteroli i postupci njihovog korišćenja
GB2557875A (en)	2015-09-02	2018-07-04	Univ Swansea	Diagnostic methods and kits
CN114272249A (zh)	2016-04-01	2022-04-05	萨奇治疗股份有限公司	氧甾醇及其使用方法
US10752653B2 (en)	2016-05-06	2020-08-25	Sage Therapeutics, Inc.	Oxysterols and methods of use thereof
AU2017292870B2 (en)	2016-07-07	2021-10-07	Sage Therapeutics, Inc.	Oxysterols and methods of use thereof
AU2017296295B2 (en)	2016-07-11	2022-02-24	Sage Therapeutics, Inc.	C7, C12, and C16 substituted neuroactive steroids and their methods of use
EP3519422B1 (en)	2016-09-30	2022-08-31	Sage Therapeutics, Inc.	C7 substituted oxysterols and these compounds for use as nmda modulators
ES2952106T3 (es)	2016-10-18	2023-10-27	Sage Therapeutics Inc	Oxisteroles y procedimientos de utilización de los mismos
KR20250054838A (ko)	2016-10-18	2025-04-23	세이지 테라퓨틱스, 인크.	옥시스테롤 및 그의 사용 방법
JP7332478B2 (ja)	2017-03-15	2023-08-23	モデルナティエックスインコーポレイテッド	脂質ナノ粒子製剤
CN110945006A (zh)	2017-06-23	2020-03-31	英特塞普特医药品公司	用于制备胆汁酸衍生物的方法和中间体
SG10202110563YA (en)	2017-11-10	2021-11-29	Marinus Pharmaceuticals Inc	Ganaxolone for use in treating genetic epileptic disoders

2016
- 2016-07-06 RS RS20211000A patent/RS62220B1/sr unknown
- 2016-07-06 JP JP2017568203A patent/JP2018519328A/ja not_active Withdrawn
- 2016-07-06 LT LTEP20214736.9T patent/LT3812392T/lt unknown
- 2016-07-06 SG SG10202002655VA patent/SG10202002655VA/en unknown
- 2016-07-06 PT PT202147369T patent/PT3812392T/pt unknown
- 2016-07-06 SM SM20210476T patent/SMT202100476T1/it unknown
- 2016-07-06 FI FIEP20214736.9T patent/FI3812392T3/fi active
- 2016-07-06 MX MX2020010690A patent/MX390271B/es unknown
- 2016-07-06 IL IL282048A patent/IL282048B2/en unknown
- 2016-07-06 PH PH1/2020/551586A patent/PH12020551586A1/en unknown
- 2016-07-06 HU HUE20214736A patent/HUE071964T2/hu unknown
- 2016-07-06 SI SI201631911T patent/SI3812392T1/sl unknown
- 2016-07-06 PL PL16821926T patent/PL3319612T3/pl unknown
- 2016-07-06 CN CN202411074416.8A patent/CN118994288A/zh active Pending
- 2016-07-06 CN CN202110635348.8A patent/CN113501855A/zh active Pending
- 2016-07-06 HR HRP20211282TT patent/HRP20211282T1/hr unknown
- 2016-07-06 DK DK16821926.9T patent/DK3319612T3/da active
- 2016-07-06 RS RS20250662A patent/RS66996B1/sr unknown
- 2016-07-06 CN CN201680050744.1A patent/CN108135911B/zh active Active
- 2016-07-06 PL PL20214736.9T patent/PL3812392T3/pl unknown
- 2016-07-06 KR KR1020187003209A patent/KR20180026742A/ko not_active Ceased
- 2016-07-06 LT LTEP16821926.9T patent/LT3319612T/lt unknown
- 2016-07-06 HR HRP20250799TT patent/HRP20250799T1/hr unknown
- 2016-07-06 CA CA2991313A patent/CA2991313C/en active Active
- 2016-07-06 KR KR1020247037600A patent/KR20240166589A/ko active Pending
- 2016-07-06 ES ES20214736T patent/ES3036110T3/es active Active
- 2016-07-06 DK DK20214736.9T patent/DK3812392T3/da active
- 2016-07-06 SI SI201631298T patent/SI3319612T1/sl unknown
- 2016-07-06 MX MX2018000280A patent/MX382122B/es unknown
- 2016-07-06 WO PCT/US2016/041175 patent/WO2017007840A1/en not_active Ceased
- 2016-07-06 MY MYPI2018000010A patent/MY197698A/en unknown
- 2016-07-06 EP EP16821926.9A patent/EP3319612B1/en active Active
- 2016-07-06 MA MA054851A patent/MA54851A/fr unknown
- 2016-07-06 EP EP20214736.9A patent/EP3812392B1/en active Active
- 2016-07-06 AU AU2016289971A patent/AU2016289971C1/en active Active
- 2016-07-06 MD MDE20180513T patent/MD3319612T2/ro unknown
- 2016-07-06 PE PE2018000037A patent/PE20180482A1/es unknown
- 2016-07-06 SM SM20250264T patent/SMT202500264T1/it unknown
- 2016-07-06 US US15/742,424 patent/US11117924B2/en active Active
- 2016-07-06 HU HUE16821926A patent/HUE055199T2/hu unknown
- 2016-07-06 PT PT168219269T patent/PT3319612T/pt unknown
- 2016-07-06 RU RU2018104245A patent/RU2742333C2/ru active
- 2016-07-06 EP EP25170345.0A patent/EP4599887A3/en active Pending
- 2016-07-06 ES ES16821926T patent/ES2884086T3/es active Active
- 2016-07-06 MX MX2021005052A patent/MX2021005052A/es unknown
2017
- 2017-12-24 IL IL256531A patent/IL256531B/en active IP Right Grant
2018
- 2018-01-05 PH PH12018500061A patent/PH12018500061A1/en unknown
- 2018-01-22 CO CONC2018/0000589A patent/CO2018000589A2/es unknown
2020
- 2020-12-24 JP JP2020215040A patent/JP2021046444A/ja not_active Withdrawn
2021
- 2021-08-06 US US17/396,034 patent/US11732000B2/en active Active
- 2021-08-13 CY CY20211100733T patent/CY1124620T1/el unknown
- 2021-08-20 AU AU2021218230A patent/AU2021218230B2/en active Active
2022
- 2022-01-19 IL IL289976A patent/IL289976B1/en unknown
- 2022-06-03 JP JP2022091046A patent/JP7602512B2/ja active Active
2023
- 2023-06-29 US US18/216,057 patent/US20240132535A1/en active Pending
2024
- 2024-01-15 AU AU2024200254A patent/AU2024200254B2/en active Active
- 2024-12-06 JP JP2024213248A patent/JP2025026574A/ja active Pending

Also Published As

Publication number	Publication date
NZ777721A (en)	2024-10-25
AU2021218230B2 (en)	2023-11-16
ES3036110T3 (en)	2025-09-12
RS66996B1 (sr)	2025-08-29
HRP20250799T1 (hr)	2025-09-12
EP4599887A3 (en)	2025-10-15
RU2742333C2 (ru)	2021-02-04
EP3319612A1 (en)	2018-05-16
JP7602512B2 (ja)	2024-12-18
NZ738849A (en)	2024-10-25
PE20180482A1 (es)	2018-03-07
LT3812392T (lt)	2025-08-11
MD3319612T2 (ro)	2021-10-31
RU2021100377A (ru)	2021-05-18
RU2018104245A3 (pl)	2019-10-31
DK3319612T3 (da)	2021-08-23
IL282048A (en)	2021-05-31
MX382122B (es)	2025-03-13
US11732000B2 (en)	2023-08-22
KR20240166589A (ko)	2024-11-26
WO2017007840A1 (en)	2017-01-12
AU2016289971C1 (en)	2022-12-08
AU2016289971B2 (en)	2021-09-09
AU2024200254B2 (en)	2026-02-26
CN108135911A (zh)	2018-06-08
CA2991313A1 (en)	2017-01-12
PT3319612T (pt)	2021-08-24
SI3812392T1 (sl)	2025-09-30
DK3812392T3 (da)	2025-07-21
PT3812392T (pt)	2025-07-21
HUE071964T2 (hu)	2025-10-28
US20220048943A1 (en)	2022-02-17
SMT202100476T1 (it)	2021-09-14
CN108135911B (zh)	2021-06-25
CN113501855A (zh)	2021-10-15
BR112018000205A2 (pt)	2018-09-04
LT3319612T (lt)	2021-08-25
AU2021218230A1 (en)	2021-09-09
FI3812392T3 (fi)	2025-07-11
HRP20211282T1 (hr)	2021-11-12
ES2884086T3 (es)	2021-12-10
US11117924B2 (en)	2021-09-14
IL282048B2 (en)	2024-09-01
MX2020010690A (es)	2022-02-25
MY197698A (en)	2023-07-06
EP3812392A1 (en)	2021-04-28
RS62220B1 (sr)	2021-09-30
JP2021046444A (ja)	2021-03-25
EP3319612B1 (en)	2021-05-19
AU2024200254A1 (en)	2024-02-01
CY1124620T1 (el)	2022-07-22
AU2016289971A1 (en)	2018-01-25
IL289976B1 (en)	2025-12-01
EP3319612A4 (en)	2019-03-06
EP3812392B1 (en)	2025-04-16
CO2018000589A2 (es)	2018-07-10
JP2022107795A (ja)	2022-07-22
CA2991313C (en)	2023-12-19
MX2018000280A (es)	2018-03-08
MX2021005052A (es)	2022-10-11
EP4599887A8 (en)	2025-09-24
IL256531B (en)	2021-04-29
PL3812392T3 (pl)	2025-09-08
JP2025026574A (ja)	2025-02-21
US20180194797A1 (en)	2018-07-12
CN118994288A (zh)	2024-11-22
JP2018519328A (ja)	2018-07-19
EP4599887A2 (en)	2025-08-13
PH12018500061A1 (en)	2018-07-23
KR20180026742A (ko)	2018-03-13
IL289976A (en)	2022-03-01
HUE055199T2 (hu)	2021-11-29
PH12020551586A1 (en)	2023-07-31
US20240132535A1 (en)	2024-04-25
MX390271B (es)	2025-03-20
MA54851A (fr)	2021-12-08
SG10202002655VA (en)	2020-05-28
RU2018104245A (ru)	2019-08-07
IL282048B1 (en)	2024-05-01
IL256531A (en)	2018-02-28
SI3319612T1 (sl)	2021-11-30
SMT202500264T1 (it)	2025-09-12

Publication	Publication Date	Title
FIC20230014I1 (fi)	2023-03-31	Foslevodopa ja foskarbidopa
IL293377A (en)	2022-07-01	Hsd17b13 variants and uses thereof
IL282048A (en)	2021-05-31	Oxysterols and methods of use thereof
PL3265448T3 (pl)	2022-04-25	Proleki riluzolu i ich zastosowanie
IL280863A (en)	2021-04-29	Autotaxin inhibitors and uses thereof
PL3295951T3 (pl)	2020-10-05	Przeciwciała anty-pvrig i sposoby ich zastosowania
PL3280441T3 (pl)	2022-02-21	Przeciwciała przeciwko sortilinie i sposoby ich stosowania
PL3828194T3 (pl)	2025-09-22	Oksysterole i sposoby ich stosowania
PL3148579T3 (pl)	2021-07-19	Przeciwciała anty-gitr i sposoby ich zastosowania
PL3373755T3 (pl)	2021-12-27	Część do e-palenia i urządzenie do e-palenia oraz sposób ich wytwarzania
PL3157552T3 (pl)	2020-05-18	Polipeptydy syntac i ich zastosowania
EP3302442C0 (en)	2024-10-16	DOSAGE FORMS AND THEIR USE
PL4234581T3 (pl)	2026-01-26	Przeciwciała terapeutyczne i ich zastosowania
EP3205103C0 (en)	2024-08-14	INTER AND INTRA UNIFICATION BLOCK COPY
MA40933A (fr)	2017-09-19	Difluorométhyl-aminopyridines et difluorométhyl-aminopyrimidines
EP3334706A4 (en)	2019-03-13	PILLARARES AND USES THEREOF
EP3511407A4 (en)	2020-04-08	CHRISTENSENELLA INTESTINIHOMINIS AND APPLICATION THEREOF
EP3350489A4 (en)	2019-04-17	VALVE AND COUPLING
DK3128005T3 (da)	2021-06-28	Sirp-alfa-variantkonstruktioner og anvendelser deraf
DK3672948T3 (da)	2022-12-05	Pyridinamin-pyridon- og pyrimidinamin-pyridonforbindelser
IL258856A (en)	2018-06-28	Solabegron zwitterion and uses thereof
DK3321279T3 (da)	2020-03-09	Exenatidmodificeringsmiddel og anvendelse deraf
PL3337506T3 (pl)	2022-01-03	Kombinacje i ich zastosowania
MA49905A (fr)	2021-03-24	Polyesteramines et polyesterquats
EP3424705A4 (en)	2019-11-27	LAMINATE AND APPLICATION THEREOF